CANF Latest Press Releases

-- September 9, 2026 --

Can-Fite: Publication Reports Improvement in Decompensated Cirrhosis with Namodenoson and Successful Bridging to Liver Transplantation Globe Newswire 7:00 AM

-- September 8, 2026 --

Can-Fite Reports Q2 2026 Financial Results and Ongoing Clinical Progress Highlighting Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study Globe Newswire 8:20 AM

-- September 2, 2026 --

Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds Globe Newswire 9:02 AM

Can-Fite Reports Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study Globe Newswire 7:00 AM

-- August 17, 2026 --

Can-Fite: Namodenoson Enhances the Anti-Cancer Effect of Chemotherapy in Pancreatic Cancer Globe Newswire 7:00 AM

-- August 12, 2026 --

Can-Fite Highlights Advanced FDA and EMA Regulatory Status of its Phase III Drug Candidates Globe Newswire 7:00 AM

-- August 3, 2026 --

Can-Fite Launches First Clinical Program for Piclidenoson in the Rare Genetic Disease Lowe Syndrome Globe Newswire 7:00 AM

-- July 20, 2026 --

Can-Fite Positive Phase 2a Pancreatic Cancer Study Data Accepted for Presentation at ESMO Congress 2026, One of the World's Premier Scientific Meetings in Oncology Globe Newswire 7:00 AM

-- July 14, 2026 --

Can-Fite Secures Australian Patent Allowance Supporting Namodenoson Development and Marketing in Liver and Pancreatic Cancer Globe Newswire 7:00 AM

-- July 6, 2026 --

Can-Fite Achieves Key Pivotal Phase 3 Psoriasis Milestone with Completion of Patient Enrolment for the Interim Analysis: Data Expected Q4 2026/Q1 2027 Globe Newswire 7:00 AM

-- July 1, 2026 --

Can-Fite Phase 2a Pancreatic Cancer Study with Namodenoson Achieves Primary Safety Endpoint and Demonstrates Durable Survival Outcomes in Advanced Disease Globe Newswire 7:00 AM

-- June 26, 2026 --

Can-Fite Secures Japanese Patent Allowance for Namodenoson's Anti-Obesity Technology Globe Newswire 7:00 AM

-- June 22, 2026 --

Can-Fite Publishes Peer-Reviewed Scientific Article Demonstrating the Broad Therapeutic Potential of Piclidenoson and Namodenoson Globe Newswire 7:00 AM

-- June 17, 2026 --

Can-Fite to Present Late-Stage Clinical Pipeline and Licensing Opportunities at BIO International Convention 2026 Globe Newswire 7:00 AM

-- June 2, 2026 --

Can-Fite Reports Positive Clinical Observation in Phase 2a Pancreatic Cancer Study and Highlights Namodenoson's RAS Signaling Inhibition Mechanism Globe Newswire 7:00 AM

Market Data Delayed 15 Minutes